anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
INTRODUCTION: Oral frailty leads to poor nutritional status, which, in turn, leads to frailty. This cross-sectional study aimed to determine regional differences in the prevalence of oral frailty and to identify factors associated with oral frailty using 3-level multilevel models.
METHODS: This study comprised 165,164 participants aged ≥65 y without long-term care requirements in the Japan Gerontological Evaluation Study. The dependent variable was oral frailty, which was calculated based on age, number of teeth, difficulty in eating tough foods, and choking. The individual-level independent variables included sociodemographics, present illness, social participation, frequency of meeting friends, and social capital. The local district-level independent variable was social capital (n = 1,008) derived from exploratory factor analyses. The municipality-level independent variable was population density (n = 62). Three-level multilevel Poisson regression analysis was performed to calculate the prevalence ratios (PRs).
RESULTS: The prevalence of oral frailty in municipalities ranged from 39.9% to 77.6%. Regarding district-level factors, higher civic participation was significantly associated with a lower probability of oral frailty. At the municipality level, the PR of the rural-agricultural area was 1.17 (95% confidence interval, 1.11-1.23) (reference: metropolitan).
CONCLUSION: These results highlight the usefulness of oral frailty prevention measures in encouraging social participation in rural areas.
KNOWLEDGE TRANSFER STATEMENT: The results of the present study showed regional differences in oral frailty. In particular, rural-agricultural areas show higher prevalence rates of oral frailty than those in metropolitan cities. Promoting measures of social participation among older adults may help prevent oral frailty in rural areas.
The invention belongs to the field of molecular biology, and particularly relates to an esophageal cancer marker, a primer, a kit and application. The esophageal cancer marker disclosed by the invention is a serum miRNA marker. The marker comprises: one or more of hsa-miR-1915-5p, hsa-miR-3177-5p, hsa-miR-5008-3p, hsa-miR-9500 and hsa-miR-12117, and a corresponding coding nucleotide sequence of each microRNA is shown as SEQ ID NO. 1-SEQ ID NO. 5. The serum miRNA has the characteristics of good stability, easy acquisition by micro-invasion and high sensitivity and specificity, and the application of the blood microRNA as an esophageal cancer screening or diagnosis marker has noninvasive and efficient effects in detection and has wide application prospects in preparation of esophageal cancer screening and diagnosis kits.
BACKGROUND: Hepatitis B virus (HBV)-specific T cell response is a major host immune response to control the virus. However, it is still unclear how it affects long-term outcomes of chronic hepatitis B patients, especially those who stop nucleos(t)ide analogue (NA) therapy. We aimed to explore whether the HBV-specific T cell response at the end of treatment (EOT) was associated with clinical outcomes.
METHODS: In a prospective cohort study, 51 HBeAg-negative patients who discontinued NA therapy were enrolled.
RESULTS: In a mean follow-up of 25.3 months, 25 patients developed clinical relapse. We found that a stronger hepatitis B core (HBc)-specific T cell response at EOT was associated with a lower risk of clinical relapse. Compared to the low-response group, the high-response group had a lower risk of clinical relapse with hazard ratio of 0.21 (95% CI: 0.05-0.88). The high HBc-specific T cell response was associated with reduced surge of HBV DNA and HBcrAg during the first year of follow-up. The T cell response at EOT was comparable between different NA treatments. Notably, the overall HBV-specific T cell response could be partially restored along with clinical relapse; however, such reinvigorated T cell response was not associated with HBsAg seroclearance.
CONCLUSIONS: A higher HBc-specific T cell response at EOT was associated with lower risk of clinical relapse and reduced surge of HBV DNA and HBcrAg levels off NA therapy.
Treatment B will be applied to the right buttock of participants on Day 1 in Period 1 followed by Treatment A to the left buttock on Day 1 in Period 2. The treatment periods will be separated by a washout period of 21 days.
Beginning 1 week before the start of SABR, patients undergo a caloric restriction diet for 6-12 weeks (for the duration of radiation treatment, until post radiation follow-up appointment) consisting of reducing calorie intake by 25%. Patients undergo SABR every other day for 5 fractions. Within 4-12 weeks of completion of SABR, patients undergo surgical resection with sentinel lymph node biopsy.
BACKGROUND: Diabetes and cardiovascular diseases represent significant global health challenges, leading to organ dysfunction and increased mortality rates. Managing these conditions is complex, especially in the elderly population. The study addresses this pressing issue by exploring the application of the Chronic Illness Trajectory Framework (CITF), aiming to improve self-care and quality of life in elderly patients with diabetes and cardiovascular diseases.
METHODS: A total of 127 patients with diabetes mellitus and cardiovascular diseases admitted to the hospital were enrolled between January 2020 and January 2022. According to the implementation of CITF management mode, they were divided into a control group (62 cases, non-implementation) and an observation group (65 cases, implementation). The control group was given routine intervention, while the observation group was given CITF-based target management mode for 3 months. The changes in blood glucose, blood lipid, negative emotions, self-efficacy, self-management, compliance, and quality of life before and after intervention in both groups were observed. This study was approved by the Ethics Committee of Zhujiang Hospital.
RESULTS: After intervention, levels of fasting plasma glucose (FPG), 2h plasma glucose (2hPG), hemoglobin A1c (HbA1c), total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C), scores of self-rating depression scale (SDS), self-rating anxiety scale (SAS) and Diabetes Specific Quality of Life Scale (DSQL) were decreased (P < .05), while scores of General Self-Efficacy Scale (GSES) and Scale of the Diabetes Self-Care Activities Chinese version (SDSCA), and compliance rate were increased in both groups (P < .05). The levels of FPG, 2hPG, HbA1c, TC, TG, and LDL-C, scores of SDS, SAS, and DSQL in the observation group were lower than those in the control group (P < .001), and scores of GSES and SDSCA, and compliance rate were higher than those in the control group (P < .001). These results highlight the positive role of comprehensive intervention in improving the physical and mental health of patients with diabetes and provide strong support for the application of comprehensive intervention strategies in diabetes management.
CONCLUSION: CITF-based target management mode can alleviate negative emotions in patients with diabetes mellitus and cardiovascular diseases, improve self-management, self-efficacy, and compliance, effectively control blood glucose and lipids, and improve quality of life. The study conclusions highlight the importance of CITF management models in improving the management of patients with diabetes and cardiovascular disease. This comprehensive intervention helps reduce negative emotions, improve self-management and compliance, effectively control blood sugar and blood lipids, and improve quality of life. These results have important clinical implications and provide strong support for better care of patients with chronic diseases.
Intervention Group participants will have 7 visits. During intervention (3 months) research staff will conduct the visual skin assessment and SEM Scanner readings at face (chin, cheeks, forehead), chest, and iliac crest, and place the MBF dressings to the face (chin, cheeks, forehead), chest and iliac crest: 1.consent and preoperative, 2. MBF dressing placement, 3.) immediately following surgery in the PAR unit with the MBF dressings removed , 4.) on transfer to the floor unit, 5.) post-operative day 1, 6.) post operative day 3 and 7.) post-operative day 5 or discharge from hospital (whichever occurs first). Combined visit time will be 1 hour and 55 minutes.
The present invention relates to protein biocoacervates and biomaterials and the methods of making and using protein biocoacervates and biomaterials. More specifically the present invention relates to protein biocoacervates and biomaterials that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, coated medical devices (e.g. stents, valves . . . ), vessels, tubular grafts, vascular grafts, wound healing devices including protein suture biomaterials and biomeshes, dental plugs and implants, skin/bone/tissue grafts, tissue fillers, protein biomaterial adhesion prevention barriers, cell scaffolding and other biocompatible biocoacervate or biomaterial devices.
BACKGROUND AND PURPOSE: GLP-1 receptor agonists are clinically utilized for type 2 diabetes and obesity. In vitro and in vivo preclinical studies were performed to assess the druggability of a novel small molecule GLP-1 receptor biased agonist SAL0112.
EXPERIMENTAL APPROACH: The HTRF assay, FLIPR assay, TR-FRET assay, and PathHunter assay were utilized for in vitro studies. Liver transporter tests were conducted using the HEK293-OATP1B1 and HEK293-OATP1B3 cell lines. In vitro stability assessments of various species and in vivo PK studies in rodents were performed. A model of type 2 diabetes and obesity induced by a high-energy diet in transgenic C57BL/6 mice expressing the human GLP-1 receptor gene was conducted.
PRINCIPAL RESULTS: SAL0112 demonstrated high potency and selectivity in activating the Gαs pathway of the GLP-1 receptor, with no observed desensitization. SAL0112 demonstrated greater stability in human and rat liver microsomes compared to Danuglipron. In vivo PK studies revealed higher absorption of SAL0112 in rats. SAL0112 displayed a significantly lower potential for DDI on liver transporters compared to Danuglipron. SAL0112 led to significant reductions in body weight (P<0.001), blood glucose levels in OGTT (P<0.001), HbA1c (P<0.05) and improved insulin resistance (P<0.01). Notably, it increased peripheral adipocyte density and resolved hepatic steatosis. The efficacy of SAL0112 was found to be comparable to that of Danuglipron and Liraglutide.
CONCLUSION: SAL0112 demonstrated potent and selective GLP-1 receptor biased agonism, effectively alleviating signs of type 2 diabetes in a mouse model. These promising findings pave the way for the advancement of SAL0112 into clinical trials.
Disclosed are methods of identifying elements associated with a trait, such as a disease. The methods can comprise, for example, identifying the association of a relevant element (such as a genetic variant) with a relevant component phenotype (such as a disease symptom) of the trait, wherein the association of the relevant element with the relevant component phenotype identifies the relevant element as an element associated with the trait, wherein the relevant component phenotype is a component phenotype having a threshold value of severity, age of onset, specificity to the trait or disease, or a combination, wherein the relevant element is an element having a threshold value of importance of the element to homeostasis relevant to the trait, intensity of the perturbation of the element, duration of the effect of the element, or a combination. The disclosed methods are based on a model of how elements affect complex diseases. The disclosed model is based on the existence of significant genetic and environmental heterogeneity in complex diseases. Thus, the specific combinations of genetic and environmental elements that cause disease vary widely among the affected individuals in a cohort. The disclosed model is an effective, general experimental design and analysis approach for the identification of causal variants in common, complex diseases by medical sequencing. The disclosed model and the disclosed methods based on the model can be used to generate valuable and useful information.
Carcinogenesis The carcinogenic potential of orally administered frovatriptan was evaluated in an 84-week study in mice (4, 13, and 40 mg/kg/day), a 104-week study in rats (8.5, 27, and 85 mg/kg/day), and a 26-week study in p53(+/-) transgenic mice (20, 62.5, 200, and 400 mg/kg/day). Although a maximum tolerated dose was not achieved in the 84-week mouse study and in female rats, plasma exposures at the highest doses studied were higher than that achieved in humans at the MRHD of 7.5 mg/day. There were no increases in tumor incidence in the 84-week mouse study at doses producing plasma exposures (AUC) 140 times that in humans at the MRHD. In the rat study, there was a statistically significant increase in the incidence of pituitary adenomas in males only at 85 mg/kg/day, a dose associated with a plasma AUC 250 times that in humans at the MRHD. In the 26-week p53(+/-) transgenic mouse study, the incidence of subcutaneous sarcomas was increased in females at doses of 200 and 400 mg/kg/day. These sarcomas were associated with subcutaneously implanted animal identification transponders, and are not considered to be relevant to humans. There were no other increases in tumor incidence of any type in any dose group. Mutagenesis Frovatriptan was clastogenic in human lymphocyte cultures, in the absence of metabolic activation. In the bacterial reverse mutation assay (Ames test), frovatriptan produced an equivocal response in the absence of metabolic activation. Frovatriptan was negative in an in vitro mouse lymphoma tk assay and an in vivo mouse bone marrow micronucleus test. Impairment of Fertility Male and female rats were dosed orally with frovatriptan prior to and during mating and in females up to implantation, at doses of 100, 500, and 1000 mg/kg/day (equivalent to approximately 130, 650, and 1300 times the MRHD on a mg/m2 basis). At all dose levels, there was an increase in the number of females that mated on the first day of pairing compared to control animals. This occurred in conjunction with a prolongation of the estrous cycle. In addition, females had a decreased mean number of corpora lutea, and consequently a lower number of live fetuses per litter, which suggested a partial impairment of ovulation. There were no other fertility-related effects.
Patients receive sunitinib malate PO QD on days 1-28. Cycles repeat every 42 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT at screening and on study, undergo bone scan as clinically indicated, and undergo collection of plasma and serum samples at screening, on study, and during follow up.
Participants received eight 21-day cycles of rituximab, combined with six or eight cycles of standard cyclophosphamide, doxorubicin, vincristine, and prednisone/prednisolone (CHOP) chemotherapy (21-day cycles). Prior to study start, study centers chose whether they planned to administer 6 or 8 cycles of CHOP chemotherapy.
<P>PROBLEM TO BE SOLVED: To obtain a stabilized α-lipoic acid composition suppressing change in quality and deterioration of an α-lipoic acid and a composition in a mode for industrially effectively making good use of the stabilized α-lipoic acid composition in industry.  <P>SOLUTION: The stabilized α-lipoic acid composition is obtained by coating the external surface of α-lipoic acid powder and/or particle with a lipid. The stabilized α-lipoic acid is obtained by coating the external surface of α-lipoic acid powder and/or particle with a lipid and further coating the resulting external surface with a hydrophilic substance. The stabilized α-lipoic acid composition is obtained by using one or more kinds selected from the group consisting of rind of Garcinia Cambogia, rhizome of Astilbe thunbergii, leaves of Psidium guajava L., and carnitine besides the composition. The α-lipoic acid is preferably an optical racemic isomer and the lipid has preferably ≥ about 40°C melting point. The food and beverage and the feed contain the stabilized α-lipoic acid composition.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Provided are: an antibody-inducing polypeptide that is useful for preventing or treating SARS-CoV-2 infections in a subject; and a vaccine including the antibody-inducing polypeptide. This polypeptide has antibody-inducing ability and is selected from a group of polypeptides described in (a)-(f): (a) polypeptides having 7 or more consecutive amino acid residues located in a region at position 336-361, position 406-432, or position 446-480 in SEQ ID NO. 1; (b) polypeptides having an amino acid sequence that has a sequence identity of 80% or more with respect to the amino acid sequence of any one of the polypeptides described in (a); (c) polypeptides each including a polypeptide described in (a) or (b) as a partial sequence but not including a region other than said partial sequence in SEQ ID NO. 1 ; (d) polypeptides having 10 or more consecutive amino acid residues located in a region at position 1144-1161 or position 1174-1202 of SEQ ID NO. 1; (e) polypeptides having an amino acid sequence that has a sequence identity of 80% or more with respect to the amino acid sequence of any one of the polypeptides described in (d); and (f) polypeptides each including a polypeptide described in (d) or (e) as a partial sequence but not including a region other than said partial sequence in SEQ ID NO. 1.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing the ongoing global pandemic associated with morbidity and mortality in humans. Although disease severity correlates with immune dysregulation, the cellular mechanisms of inflammation and pathogenesis of COVID-19 remain relatively poorly understood. Here, we used mouse-adapted SARS-CoV-2 strain MA10 to investigate the role of adaptive immune cells in disease. We found that while infected wild-type mice lost ~10% weight by 3 to 4 days postinfection, rag-/- mice lacking B and T lymphocytes did not lose weight. Infected lungs at peak weight loss revealed lower pathology scores, fewer neutrophils, and lower interleukin-6 and tumor necrosis factor-α in rag-/- mice. Mice lacking αβ T cells also had less severe weight loss, but adoptive transfer of T and B cells into rag-/- mice did not significantly change the response. Collectively, these findings suggest that while adaptive immune cells are important for clearing SARS-CoV-2 infection, this comes at the expense of increased inflammation and pathology.
PROBLEM TO BE SOLVED: To obtain a hair-washing agent capable of washing stained hair and simultaneously recovering thin hair, damaged hair, and cut hair, branched hair into normal black hair by adding a specific oil originated from a natural oil in a specific amount to a system containing glycerol and a surfactant. SOLUTION: This hair-washing agent contains 2-8wt.% of glycerol, 45-65wt.% of a surfactant and further 0.5-10wt.%, especially 1-5wt.%, of an orange oil as water-removed components for the washing agent. The orange oil is obtained by subjecting the pericarp of an orange belonging to the family Ruta, such as sweet orange, bitter orange or summer mandarin orange as a raw material to a treatment such as a pressing treatment, a vacuum-pressing treatment, an alkali treatment or a steam distillation treatment. The orange oil contains >=80wt.% of d-limonene as a main component and the balance of n- decylaldehyde, citral, d-linarool, etc. The hair-washing agent can suppress the dandruff and itching of scalps. When the hair-washing agent is used for business, the hand fingers of users are not roughened.
Serious cases of herpes zoster have occurred with TECFIDERA, including disseminated herpes zoster, herpes zoster ophthalmicus, herpes zoster meningoencephalitis, and herpes zoster meningomyelitis. These events may occur at any time during treatment. Monitor patients on TECFIDERA for signs and symptoms of herpes zoster. If herpes zoster occurs, appropriate treatment for herpes zoster should be administered. 

Other serious opportunistic infections have occurred with TECFIDERA, including cases of serious viral (herpes simplex virus, West Nile virus, cytomegalovirus), fungal (Candida and Aspergillus), and bacterial (Nocardia, Listeria monocytogenes, Mycobacterium tuberculosis) infections. These infections have been reported in patients with reduced absolute lymphocyte counts (ALC) as well as in patients with normal ALC. These infections have affected the brain, meninges, spinal cord, gastrointestinal tract, lungs, skin, eye, and ear. Patients with symptoms and signs consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment. 

Consider withholding TECFIDERA treatment in patients with herpes zoster or other serious infections until the infection has resolved [see Adverse Reactions (6.2)].
In this group, the patients who have tumor of Her-2 positive will receive regular Trastuzumab to decrease tumor burden. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).
INTRODUCTION: This study investigated the prevalence of sleep disturbances among people living with type 2 diabetes in Saudi Arabia.
METHODS: A four-stage sampling method was used to recruit 479 participants from various parts of the country. A self-administered questionnaire was used to collect demographic, sleep disruption, and related clinical characteristics. Data analysis included reporting sleep disturbance prevalence as frequency and percentage, chi-square tests to examine categorical variable associations, and multiple logistic regression analysis to identify independent factors associated with sleep disturbances.
RESULTS: The data showed that most participants were male (59.3%), married (78.5%), and Diploma/ Bachelor's degree holders (41.5%). The study found that most respondents had subjective sleep quality issues, with 55.3% of Sleep Latency participants having trouble falling asleep, 62.4% having trouble sleeping, 65.1% experiencing serious sleep efficiency impairment, 85.2% reporting sleep difficulties, 88.5% using sleep medication without difficulty, 5.4% having moderate difficulty, and 6.1% having considerable difficulties. The Global Pittsburgh Sleep Quality Index (PSQI) showed that all participants had sleep problems. Marital status, nationality, HBA1C, education, region, comorbidity, and monthly income were significantly associated with sleep disturbance characteristics.
CONCLUSION: The study concluded that diabetes itself can increase the risk of sleep problems, as it is associated with various sleep-related issues such as insomnia, sleep apnea, and restless legs syndrome. Encouraging social support within the realm of healthcare services holds significance in reducing the occurrence of inadequate sleep. For individuals diagnosed with type 2 diabetes mellitus, managing their blood sugar levels effectively is crucial for enhancing the quality of their sleep. Furthermore, engaging in regular physical activity is essential for preventing subpar sleep quality.
In the first intervention period the subjects will receive placebo. There will be a 3 week washout period. In the second intervention period, the subjects will receive an infusion of ANX-042.
A novel factor is described having neutrophil-stimulating activity and isolated from blood leukocytes and/or platelets. It is structurally and functionally related to neutrophil-activating factor NAF/NAP-1 and is also structurally related to ß-thromboglobulin, PBP and CTAP-III. The sequence has been established. The molecular weight of the factor is approximately 6500-7700. 3 variants have also been found. The factor can be prepared from natural sources or by recombinant DNA techniques.